Kenya Launches First HIV Prevention Injection

Kenya has initiated the deployment of a pioneering HIV prevention medication, lenacapavir, beginning in a slum area in Nairobi on Thursday.

Lenacapavir, which is administered twice annually, has demonstrated an ability to reduce the chances of HIV transmission by over 99.9%. However, it is classified as a chemical drug rather than a vaccine due to its method of action, which does not stimulate the immune system.

Health Minister Aden Duale expressed optimism during the rollout, stating, “Today is a moment of hope for thousands of Kenyan families.”

Last year, Kenya was selected as one of nine African nations to incorporate lenacapavir into their healthcare systems; the drug had already been introduced in South Africa, Eswatini, and Zambia since December.

Currently, approximately 1.3 million individuals are living with HIV in Kenya, with the burden most pronounced among those aged between 15 and 24.

Duale further highlighted, “Many of our young people still face the risk of infection… this innovation gives us renewed strength in our national fight against HIV.” He assured that the medication would be provided free of charge to recipients.

Moreover, just last week, Kenya received its initial shipment of 21,000 doses through a partnership with Gilead Sciences, the drug's producer, and the Global Fund to Fight AIDS.

This rollout coincides with challenges faced by several African countries as they adjust to cuts in U.S. aid that have impacted HIV/AIDS initiatives across the continent.